Immune checkpoint blockade has revolutionized the field of oncology, inducing durable anti-
tumour immunity in solid tumours. In patients with advanced prostate cancer …

Unlike several other tumor types, prostate cancer rarely responds to immune checkpoint
blockade (ICB). To define tumor cell intrinsic factors that contribute to prostate cancer …

Immunotherapies that block inhibitory checkpoint receptors on T cells have transformed the
clinical care of patients with cancer. However, whether the T cell response to checkpoint …

A significant fraction of patients with advanced prostate cancer treated with androgen
deprivation therapy experience relapse with relentless progression to lethal metastatic …

Despite their key regulatory role and therapeutic potency, the molecular signatures of
interactions between T cells and antigen-presenting myeloid cells within the tumor …

Immune checkpoint inhibitors result in impressive clinical responses,,,, but optimal results
will require combination with each other and other therapies. This raises fundamental …

Immunotherapies that enhance the ability of the immune system to target cancer cells have
proven effective in a variety of tumor types, yet clinical responses vary across patients and …

Abstract Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and
ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung …

Immune-checkpoint blockade (ICB) has shown remarkable clinical success in boosting
antitumor immunity. However, the breadth of its cellular targets and specific mode of action …

Solid tumours are highly refractory to immune checkpoint blockade (ICB) therapies due to
the functional impairment of effector T cells and their inefficient trafficking to tumours. T-cell …